Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.

ABSTRACT: Adenoviruses (Ad) are commonly used both experimentally and clinically, including oncolytic virotherapy applications. In the clinical area, efficacy is frequently hampered by the high rates of neutralizing immunity, estimated as high as 90% in some populations that promote vector clearance and limit bioavailability for tumor targeting following systemic delivery. Active tumor targeting is also hampered by the ubiquitous nature of the Ad5 receptor, hCAR, as well as the lack of highly tumor-selective targeting ligands and suitable targeting strategies. Furthermore, significant off-target interactions between the viral vector and cellular and proteinaceous components of the bloodstream have been documented that promote uptake into non-target cells and determine dose-limiting toxicities. Novel

SUBMITTER: Uusi-Kerttula H 

PROVIDER: S-EPMC4664994 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature